Pfizer and Sanofi-Aventis Exubera

phealthDiabetics_730.jpg

Daily insulin injections make it hard
for many diabetics to control blood sugar well enough to prevent serious complications like blindness and kidney failure. Now Pfizer and Sanofi-Aventis offer up the painless Exubera, an inhaler that delivers aerosolized insulin to the lungs, which quickly absorb the drug over their large surface area. A single puff just before meals can stabilize blood sugar as effectively as a shot. A Food and Drug Administration panel voted to approve Exubera this fall based on results from more than 52 clinical trials conducted over 10 years.